Cara Therapeutics (CARA) Misses Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. COF
7. GOOGL
8. RTX
9. TSLA
10. BRZE

Go back to Cara Therapeutics (CARA) Misses Q1 EPS by 7c

Cara Therapeutics Reports First Quarter 2017 Financial Results

May 4, 2017 4:01 PM EDT

 Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus  

 Completed public offering of common stock, raising net proceeds of $86.5 million  

Conference call today at 4:30 p.m. ET

STAMFORD, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial... More